Liothyronine
- Atc Codes:H03AA02
- CAS Codes:55-06-1#6893-02-3
- PHARMGKB ID:55-06-1#6893-02-3
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
France: Cynomel; Germany: Thybon, Thyrotardin, Trijodthyronin; Greece: Cynomel, T3, Triiodothyronine, Trijodhyronin; Ireland: Tertroxin, Triiodothyronine; Italy: Dispon, Ti-Tre; Luxembourg: Cytomel; Malta: Triiodothyronine; Netherlands: Cytomel; Portugal: Neo-Tiroimade; Sweden: Liothyronin; UK: Liothyronin, Triiodothyronine.
North America
Canada: Cytomel; USA: Cytomel, Liothyronine, Triostat.
Latin America
Argentina: Tri Iodo Tironina; Mexico: Cynomel, Triyotrex.
Asia
Japan: Thyronamin, Thyronine.
Drug combinations
Liothyronine and Levothyroxine
Chemistry
Liothyronine Sodium: C~15~H~11~I~3~NNaO~4~. Mw: 672.96. (1) L-Tyrosine, O-(4-hydroxy-3-iodophenyl)-3,5-diiodo-, monosodium salt; (2) Monosodium L-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]alanine. CAS-55-06-1; CAS-6893-02-3 (liothyronine).
Pharmacologic Category
Thyroid Agents. (ATC-Code: H03AA02).
Mechanism of action
It is believed the thyroid hormone exerts its many metabolic effects through control of DNA transcription and protein synthesis. Involved in normal metabolism, growth, and development. Promotes gluconeogenesis, increases utilization and mobilization of glycogen stores, and stimulates protein synthesis, increases basal metabolic rate.
Therapeutic use
Replacement or supplemental therapy in hypothyroidism. Management of nontoxic goiter. Diagnostic aid. Treatment of myxedema coma/precoma.
Pregnancy and lactiation implications
Untreated hypothyroidism may have adverse effects on fetal growth and development, and is associated with higher rate of complications. Treatment should not be discontinued during pregnancy. Enters breast milk (small amounts).
Unlabeled use
Contraindications
Hypersensitivity to liothyronine or any component of the formulation. Undocumented or uncorrected adrenal insufficiency. Recent MI or thyrotoxicosis. Artificial rewarming (injection).
Warnings and precautions
Use with caution in adrenal insufficiency, diabetes mellitus and insipidus, and in myxedema (symptoms may be exaggerated or aggravated). Use with caution in angina pectoris or other cardiovascular disease, or in elderly patients (likely to have compromised cardiovascular function). Thyroid supplements ineffective and potentially toxic for weight reduction. High doses may produce serious or even life-threatening toxic effects particularly when used with some anorectic drugs.